Inhibikase Therapeutics, Inc. (IKT) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
16/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinIKT / S&P 20.83% / 15.20% |
LoseIKT / S&P IKT unavailable / 15.00% |
WinIKT / S&P 975.00% / 50.40% |
| 2026-Q10/3 |
LoseIKT / S&P -18.05% / -4.33% |
LoseIKT / S&P IKT unavailable / 11.30% |
LoseIKT / S&P -27.12% / 27.70% |
| 2025-Q41/3 |
WinIKT / S&P 26.54% / 2.65% |
LoseIKT / S&P IKT unavailable / 9.00% |
LoseIKT / S&P -58.97% / 13.40% |
| 2025-Q30/3 |
LoseIKT / S&P -16.92% / 8.12% |
LoseIKT / S&P -100.00% / 4.61% |
LoseIKT / S&P -121.15% / 13.45% |
| 2025-Q20/3 |
LoseIKT / S&P -10.96% / 10.94% |
LoseIKT / S&P -100.00% / 4.83% |
LoseIKT / S&P -98.39% / 10.63% |
| 2025-Q10/3 |
LoseIKT / S&P -32.62% / -4.27% |
LoseIKT / S&P -100.00% / 4.98% |
LoseIKT / S&P -79.86% / 10.57% |
| 2024-Q41/3 |
WinIKT / S&P 150.00% / 2.41% |
LoseIKT / S&P -100.00% / 5.25% |
LoseIKT / S&P -63.21% / 6.15% |
| 2024-Q31/3 |
WinIKT / S&P 7.44% / 5.89% |
LoseIKT / S&P -100.00% / 5.89% |
LoseIKT / S&P -42.82% / 6.11% |
| 2024-Q20/3 |
LoseIKT / S&P -43.98% / 4.28% |
LoseIKT / S&P -68.40% / 5.38% |
LoseIKT / S&P -40.53% / 5.12% |
| 2024-Q12/3 |
WinIKT / S&P 70.08% / 10.56% |
WinIKT / S&P 38.08% / 5.71% |
LoseIKT / S&P -29.57% / 5.59% |
| 2023-Q41/3 |
LoseIKT / S&P -8.63% / 11.69% |
WinIKT / S&P 111.03% / 6.81% |
LoseIKT / S&P -5.36% / 7.78% |
| 2023-Q32/3 |
LoseIKT / S&P -61.50% / -3.27% |
WinIKT / S&P 424.23% / 7.52% |
WinIKT / S&P 56.30% / -5.03% |
| 2023-Q21/3 |
LoseIKT / S&P -8.56% / 8.74% |
LoseIKT / S&P -34.26% / 9.50% |
WinIKT / S&P 151.20% / -8.57% |
| 2023-Q12/3 |
WinIKT / S&P 31.60% / 7.50% |
LoseIKT / S&P -91.84% / 10.77% |
WinIKT / S&P 433.33% / -15.69% |
| 2022-Q40/3 |
LoseIKT / S&P -45.05% / 7.56% |
LoseIKT / S&P -96.02% / 11.88% |
LoseIKT / S&P IKT unavailable / -17.99% |
| 2022-Q31/3 |
WinIKT / S&P 22.48% / -4.88% |
LoseIKT / S&P -98.11% / 13.47% |
LoseIKT / S&P IKT unavailable / -1.41% |
| 2022-Q20/3 |
LoseIKT / S&P -49.80% / -16.10% |
LoseIKT / S&P -87.14% / 13.71% |
LoseIKT / S&P IKT unavailable / 11.04% |
| 2022-Q11/3 |
WinIKT / S&P 0.68% / -4.60% |
LoseIKT / S&P -5.20% / 15.97% |
LoseIKT / S&P IKT unavailable / 42.23% |
| 2021-Q41/3 |
LoseIKT / S&P -22.63% / 11.03% |
WinIKT / S&P 343.92% / 15.00% |
LoseIKT / S&P IKT unavailable / 96.40% |
| 2021-Q30/3 |
LoseIKT / S&P -32.14% / 0.58% |
LoseIKT / S&P IKT unavailable / 10.77% |
LoseIKT / S&P IKT unavailable / 69.42% |
| 2021-Q20/3 |
LoseIKT / S&P -53.41% / 8.55% |
LoseIKT / S&P IKT unavailable / 6.58% |
LoseIKT / S&P IKT unavailable / 51.81% |
| 2021-Q10/3 |
LoseIKT / S&P -12.90% / 6.17% |
LoseIKT / S&P IKT unavailable / -1.06% |
LoseIKT / S&P IKT unavailable / 7.39% |
| 2020-Q40/3 |
LoseIKT / S&P IKT unavailable / 12.15% |
LoseIKT / S&P IKT unavailable / -3.72% |
LoseIKT / S&P IKT unavailable / -33.42% |
| 2020-Q30/3 |
LoseIKT / S&P IKT unavailable / 8.93% |
LoseIKT / S&P IKT unavailable / -2.04% |
LoseIKT / S&P IKT unavailable / -27.10% |
| 2020-Q20/3 |
LoseIKT / S&P IKT unavailable / 20.54% |
LoseIKT / S&P IKT unavailable / -0.46% |
LoseIKT / S&P IKT unavailable / -27.11% |
| 2020-Q10/3 |
LoseIKT / S&P IKT unavailable / -19.60% |
LoseIKT / S&P IKT unavailable / 3.47% |
LoseIKT / S&P IKT unavailable / -14.75% |
| 2019-Q40/3 |
LoseIKT / S&P IKT unavailable / 9.07% |
LoseIKT / S&P IKT unavailable / 5.36% |
LoseIKT / S&P IKT unavailable / 2.99% |
| 2019-Q30/3 |
LoseIKT / S&P IKT unavailable / 1.70% |
LoseIKT / S&P IKT unavailable / 5.02% |
LoseIKT / S&P IKT unavailable / 0.21% |
| 2019-Q20/3 |
LoseIKT / S&P IKT unavailable / 4.30% |
LoseIKT / S&P IKT unavailable / 6.64% |
LoseIKT / S&P IKT unavailable / 8.65% |
| 2019-Q10/3 |
LoseIKT / S&P IKT unavailable / 13.65% |
LoseIKT / S&P IKT unavailable / 8.12% |
LoseIKT / S&P IKT unavailable / 14.29% |
| 2018-Q40/3 |
LoseIKT / S&P IKT unavailable / -13.52% |
LoseIKT / S&P IKT unavailable / 9.05% |
LoseIKT / S&P IKT unavailable / 18.23% |
| 2018-Q30/3 |
LoseIKT / S&P IKT unavailable / 7.71% |
LoseIKT / S&P IKT unavailable / 10.21% |
LoseIKT / S&P IKT unavailable / 19.06% |
| 2018-Q20/3 |
LoseIKT / S&P IKT unavailable / 3.43% |
LoseIKT / S&P IKT unavailable / 9.03% |
LoseIKT / S&P IKT unavailable / 14.46% |
| 2018-Q10/3 |
LoseIKT / S&P IKT unavailable / -0.76% |
LoseIKT / S&P IKT unavailable / 7.68% |
LoseIKT / S&P IKT unavailable / 12.46% |
| 2017-Q40/3 |
LoseIKT / S&P IKT unavailable / 6.64% |
LoseIKT / S&P IKT unavailable / 7.03% |
LoseIKT / S&P IKT unavailable / 13.82% |
| 2017-Q30/3 |
LoseIKT / S&P IKT unavailable / 4.48% |
LoseIKT / S&P IKT unavailable / 5.68% |
LoseIKT / S&P IKT unavailable / 17.57% |
| 2017-Q20/3 |
LoseIKT / S&P IKT unavailable / 3.09% |
LoseIKT / S&P IKT unavailable / 4.83% |
LoseIKT / S&P IKT unavailable / 17.74% |
| 2017-Q10/3 |
LoseIKT / S&P IKT unavailable / 6.07% |
LoseIKT / S&P IKT unavailable / 3.67% |
LoseIKT / S&P IKT unavailable / 13.32% |
| 2016-Q40/3 |
LoseIKT / S&P IKT unavailable / 3.82% |
LoseIKT / S&P IKT unavailable / 2.09% |
LoseIKT / S&P IKT unavailable / 7.05% |
| 2016-Q30/3 |
LoseIKT / S&P IKT unavailable / 3.85% |
LoseIKT / S&P IKT unavailable / 0.20% |
LoseIKT / S&P IKT unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IKT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 37.22% | 20.78% |
| Annualized return | 37.22% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IKT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -82.99% | 83.14% |
| Annualized return | -29.83% | 12.86% |
10Y · 2020-12-23 to 2026-08-27
| Metric | IKT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -95.84% | 319.30% |
| Annualized return | -27.24% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |